SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes

Journal
Vaccines
ISSN
2076-393X
Date Issued
2022
Author(s)
Muriel Ramírez-Santana
Gloria Icaza
Loreto Nuñez-Franz
Rubén Quezada-Gate
Macarena Said
Carolina Sacristán Ramírez
Type
Resource Types::text::journal::journal article
Scopus ID
2-s2.0-85133548389
WoS ID
WOS:000831717000001
DOI
URL
URL Institutional Repository
Abstract
<jats:p>Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response.</jats:p>
Cite this document
Aguilera, X., Hormazábal, J., Vial, C., Cortes, L. J., González, C., Rubilar, P., Apablaza, M., Ramírez-Santana, M., Icaza, G., Nuñez-Franz, L., Castillo-Laborde, C., Ramírez-Riffo, C., Pérez, C., Quezada-Gate, R., Said, M., & Vial, P. (2022). Sars-cov-2 neutralizing antibodies in chile after a vaccination campaign with five different schemes. Vaccines, 10(7), 1051. https://doi.org/10.3390/vaccines10071051
Subjects
azd1222

; 

bnt162b2

; 

coronavac

; 

covid-19

; 

cross-sectional design

; 

neutralizing antibodies

; 

sars-cov-2

; 

vaccine-preventable diseases

; 

vaccines

; 

viruses

; 

coronavac

; 

neutralizing antibody

; 

tozinameran

; 

vaxzevria

; 

adolescent

; 

adult

; 

anosmia

; 

article

; 

child

; 

chile

; 

chronic obstructive lung disease

; 

coronavirus disease 2019

; 

coughing

; 

cross-sectional study

; 

diarrhea

; 

dyspnea

; 

fatigue

; 

female

; 

fever

; 

headache

; 

human

; 

human cell

; 

ic50

; 

immunization

; 

major clinical study

; 

male

; 

myalgia

; 

obesity

; 

odynophagia

; 

severe acute respiratory syndrome coronavirus 2

; 

thorax pain

; 

vaccination

; 

vaccine preventable disease

; 

vero c1008 cell line